| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 10/02/2008 | US20080242719 Reduce tumor necrosis factor; phosphodiesterase inhibitor; antiinflammatory agents; anticancer agents; antidepressants; skin diosrders |
| 10/02/2008 | US20080242718 point-of-care platelet analyzer device optimized for neuro-psychiatric analytes; testing and software predetermines risks of developing various neuropsychiatric conditions, like depression, Parkinson's, Alzheimer's, bipolar disorder, ADD/ADHD, autism, asperger's syndrome, OCD and other anxiety disorders |
| 10/02/2008 | US20080242716 Ion Channel Modulators |
| 10/02/2008 | US20080242715 Psychological disorders such as schizophrenia and sexual disorders |
| 10/02/2008 | US20080242706 neurodegenerative diseases; to remove free iron or iron accumulation in neural tissues; iron chelators; improved chemical stability, penetration through blood brain barrier; reacting 3-hydroxy-4-pyridinone/3-hydroxy-4-pyranone derivatives; 1-cyclopropyl-2-difluoromethyl-5-hydroxy-1H-pyridin-4-one |
| 10/02/2008 | US20080242699 Cyclohexylamin isoquinolone derivatives |
| 10/02/2008 | US20080242693 dopamine and nicotinic acetylcholine receptors antagonist; analgesic, antidepressant, anxiolytic agent; neurodegenerative diseases, drug and nicotine abuse, obesity; 6-(5-methoxy-3-pyridinyl)-3-azabicyclo[3.3.1]non-6-ene |
| 10/02/2008 | US20080242689 N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof |
| 10/02/2008 | US20080242688 Cognition activators, Alzheimer's disease, schizophrenia |
| 10/02/2008 | US20080242681 N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors |
| 10/02/2008 | US20080242680 Agent for the prophylaxis or treatment of neurodegenerative disease |
| 10/02/2008 | US20080242673 novel triazolopyrimidine derivatives like 7-(2-(4-(2,5-Difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-yl)-7H-pyrrolo[3,2-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine; to treat central nervous system disorders like depression, Parkinson's disease; senile dementia; psychoses etc. |
| 10/02/2008 | US20080242672 Adenosine a2a receptor antagonists |
| 10/02/2008 | US20080242669 compounds which mimic the secondary structure of alpha -helix regions of biologically active peptides and proteins; compounds are used to reverse fibrotic conditions |
| 10/02/2008 | US20080242668 Neurodegenerative, inflammatory disorders, pain, drug abuse; useful as diagnostic tools or monitoring agents such as for neuroimaging, labelling; nicotinic and/or monoamine receptors modulators; 2,2'-Bis-((+-)-1-aza-bicyclo[2.2.2]oct-3-yloxy)-[5,5']-bithiazolyl; cholinergic ligands |
| 10/02/2008 | US20080242657 Mixture with neuroleptic agent; reducing tremors from Parkinson's disease, multiple sclerosis, strokes, dystonia |
| 10/02/2008 | US20080242654 Novel compounds as cannabinoid receptor ligands |
| 10/02/2008 | US20080242653 Cyclopropyl amine derivatives |
| 10/02/2008 | US20080242652 Indole derivatives and their metal conjugates and uses thereof |
| 10/02/2008 | US20080242616 Peptide specificity of anti-myelin basis protein and the administration of myelin basic protein peptides to multiple sclerosis patients |
| 10/02/2008 | US20080242598 Short chain peptide; conformation scaffolds; diecting amino acids into positions; controlling apoptosis; tumor suppression; alcoholism; drug abuse; antiepileptic agents |
| 10/02/2008 | US20080242590 New Method 706 |
| 10/02/2008 | US20080242588 Inhibiting acid sensing ion channel 1a (ASIC1a); epilepsy; using PcTX1 or peptide derivative and/or amiloride or derivative |
| 10/02/2008 | US20080241961 Drosophila g protein coupled receptors, nucleic acids, and mehtods related to the same |
| 10/02/2008 | US20080241861 Biological materials and methods useful in the diagnosis and treatment of diseases |
| 10/02/2008 | US20080241859 Using aglycoprotein 10B antibody as diagnostic tool in detection of cell proliferative disorders associated with chronic viral diseases |
| 10/02/2008 | US20080241857 Netrin receptors |
| 10/02/2008 | US20080241283 Aqueous extracts of anoectochilus spp. kinsenoside-comprising pharmaceutical compositions useful for hepatoprotection and uses of the same |
| 10/02/2008 | US20080241280 Usage of the Plant of Genus Ampelopsis and Extracts Thereof For Manufacture of Medicament and Functional Food |
| 10/02/2008 | US20080241278 Administer amino acid precursor L-dopa, tyrosine, D,L-Phenylalanine, and N-acetyl-L-tyrosine; serotonin precursor of 5-HTP and tryptophan; and cofactors of vitamin B6, Vitamin C, Calcium, Folate, Cysteine; minimal side effects at higher doses, one precursor balances the other |
| 10/02/2008 | US20080241255 Enhanced inhalation delivery to lungs; effective for wide range of medicants |
| 10/02/2008 | US20080241239 Pharmaceutical Tablets Having a Separation Mark Positioned on the Side of Said Tablets |
| 10/02/2008 | US20080241183 Tetanus toxoids; polyclonal antibodies; antigens |
| 10/02/2008 | US20080241171 Stem Cell Populations and Methods of Use |
| 10/02/2008 | US20080241169 Using phage displayed prion specific immunoglobulin to prevent aggregation of amyloid plaques; treating alzheimer's disease |
| 10/02/2008 | US20080241165 Controlling extracellular protein degradation and/or clearance via modulation of tissue plasminogen activator activity; treating diabetic, autoimmune, cardiovascular, blood and nervous system disorders |
| 10/02/2008 | US20080241163 Tweak binding antibodies |
| 10/02/2008 | US20080241158 G-protein coupled receptors for use in identifying modulators for treatment and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, metabolic and viral disorders |
| 10/02/2008 | US20080241157 Nerve cell growth modulators (amphibodies) |
| 10/02/2008 | US20080241142 Neuropilin/VEGF-C/VEGFR-3 Materials and Methods |
| 10/02/2008 | US20080241099 Inhibitors of MBP 85-99 or proteolipid protein (PLP) 40-60-specific HLA-DR-2-restricted T cell clones; multiple sclerosis; rheumatoid arthritis; solid phase synthesis; kits |
| 10/02/2008 | US20080241097 Methods of treating neurological conditions with hematopoeitic growth factors |
| 10/02/2008 | DE102007014375A1 Oleylphosphocholin Oleylphosphocholine |
| 10/02/2008 | DE10101430B4 Lösliche cyclische Analoga zur Modulation der Amyloidogenese Soluble cyclic analogues in the modulation of amyloidogenesis |
| 10/02/2008 | CA2684655A1 Oral pharmaceutical preparation for colon-specific delivery |
| 10/02/2008 | CA2682163A1 Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments |
| 10/02/2008 | CA2681545A1 Fluorinated derivatives of deferiprone |
| 10/02/2008 | CA2681536A1 Pyrimido[4,5-d]azepine derivatives as 5-ht2c agonists |
| 10/02/2008 | CA2681404A1 Fusion protein capable of degrading amyloid beta peptide |
| 10/02/2008 | CA2681034A1 Azetidin compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 10/02/2008 | CA2681030A1 Quinoline compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 10/02/2008 | CA2680517A1 Novel pyridinecarboxylic acid (2-aminophenyl)amide derivative having urea structure |
| 10/02/2008 | CA2679885A1 Aminomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs) |
| 10/02/2008 | CA2679870A1 Azaadamantane ester and carbamate derivatives and methods of use thereof |
| 10/02/2008 | CA2677991A1 Thiazolidine derivatives |
| 10/01/2008 | EP1975176A1 Novel glp-1 fusion peptides, their production and use |
| 10/01/2008 | EP1975172A2 High affinity TGFß nucleic acid ligands and inhibitors |
| 10/01/2008 | EP1975168A1 Pyrazole carboxamide derivatives, pharmaceutical compositions and its preparation |
| 10/01/2008 | EP1975164A2 Octahydrobenzimidazolone compounds as analgetics |
| 10/01/2008 | EP1975161A1 Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments |
| 10/01/2008 | EP1974732A1 Therapeutic agent for neurodegenerative disease |
| 10/01/2008 | EP1974729A1 Substituted imidazopyridine derivates as melanocortin- 4 receptor antagonists |
| 10/01/2008 | EP1974727A1 Therapeutic agent for acute cerebral infarct |
| 10/01/2008 | EP1973911A2 Azaindoles useful as inhibitors of janus kinases |
| 10/01/2008 | EP1973907A1 Imidazo (1,2-a)pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof |
| 10/01/2008 | EP1973905A1 Compounds |
| 10/01/2008 | EP1973904A2 Muscarinic agonists and methods of use thereof |
| 10/01/2008 | EP1973885A1 Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same |
| 10/01/2008 | EP1973876A2 Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors |
| 10/01/2008 | EP1973868A1 Novel elatonin ligands having antidepressant activity as well as sleep inducing properties |
| 10/01/2008 | EP1973551A1 Method and composition for treating and diagnosing restless legs syndrome |
| 10/01/2008 | EP1973543A2 Modulators of muscarinic receptors |
| 10/01/2008 | EP1973539A1 Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
| 10/01/2008 | EP1973538A2 Method for treating huntington's disease by inhibiting dephosphorylation of huntingtin at s421 |
| 10/01/2008 | EP1973535A2 Method for the treatment of tinnitus |
| 10/01/2008 | EP1885363B1 Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease |
| 10/01/2008 | EP1868568B1 Method for preparing a ginkgo extract having a reduced content of 4'-o-methyl pyridoxine and/or biflavones |
| 10/01/2008 | EP1709161B1 Human therapeutic cells secreting nerve growth factor |
| 10/01/2008 | EP1641454B1 Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| 10/01/2008 | EP1635825B1 Synergistic combinations including n-acylated 4-hydroxyphenylamine derivatives and caffeine |
| 10/01/2008 | EP1626710B1 Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders |
| 10/01/2008 | EP1399424B8 Method for preparation of 10,11-dihydro-10-hydroxy-5h-dibenz/b,f/azepine-5-carboxamide and 10,11-dihydro-10-0x0-5h-dibenz/b,f/azepine-5-carboxamide |
| 10/01/2008 | EP1331935B1 Derivatives of tryptamine and analogous compounds, and pharmaceutical formulations containing them |
| 10/01/2008 | EP1251862B1 Ophthalmic compositions for treating ocular hypertension |
| 10/01/2008 | EP1224160B1 Process for the preparation of the polymorphic form II of sertraline hydrochloride |
| 10/01/2008 | EP1212295B1 Substituted alpha-hydroxy acid caspase inhibitors and the use thereof |
| 10/01/2008 | EP1135113B1 Treatment of parkinson's disease with oligonucleotides |
| 10/01/2008 | CN101277974A Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
| 10/01/2008 | CN101277965A N-phenyl benzamide derivatives as sirtuin modulators |
| 10/01/2008 | CN101277963A Benzimidazole derivatives as SIRTUIN modulators |
| 10/01/2008 | CN101277962A Bicyclic aromatic compounds useful as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 |
| 10/01/2008 | CN101277958A Naphthyridin derivatives |
| 10/01/2008 | CN101277957A Preparation and use of tetrahydropyrrolo [3, 2-c] pyridin-4-one derivatives for treatment of obesity, psychiatric and neurological disorders |
| 10/01/2008 | CN101277954A 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 10/01/2008 | CN101277952A Isoxazole derivatives |
| 10/01/2008 | CN101277940A 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| 10/01/2008 | CN101277933A Substituted propylamine derivatives and methods of their use |
| 10/01/2008 | CN101277739A Methods and compositions for improving cognitive function |
| 10/01/2008 | CN101277715A Treatment of neurodegenerative disorders |
| 10/01/2008 | CN101277691A Use of a PKC activator, alone or combined with a pkc inhibitor to enhance long term memory |